NCT07268066 Implementation of the Methylome in the Characterization of Solid Tumors
| NCT ID | NCT07268066 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Solid Tumor Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 180 participants |
| Start Date | 2024-05-21 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 180 participants in total. It began in 2024-05-21 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to investigate the functional consequences of specific methylation changes and to examine the clinical implications of these alterations. Methylation analysis is a powerful tool for understanding the molecular mechanisms of brain tumors and other solid tumors and can help identify new diagnostic and therapeutic targets. By analyzing DNA methylation patterns in tumor tissue, it is possible to identify genes that are silenced or activated by methylation. This information can be used to develop new biomarkers for early diagnosis and to identify new therapeutic targets that can be used to reverse methylation-mediated gene silencing.
Eligibility Criteria
Inclusion Criteria: * Confirmed diagnosis of one of the following types of cancer: gliomas, malignant thyroid neoplasms, or endometrial carcinomas (according to the WHO Nomenclature) * Availability of adequate material for analysis at the laboratory, specifically availability of at least 3 sections of 10 µm of FFPE Exclusion Criteria: * no
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07268066 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Solid Tumor Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07268066 currently recruiting?
Yes, NCT07268066 is actively recruiting participants. Contact the research team at giovanni.tallini@ausl.bologna.it for enrollment information.
Where is the NCT07268066 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT07268066 clinical trial?
NCT07268066 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 180 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.